share_log

Arcutis Biotherapeutics | EFFECT: Others

Arcutis Biotherapeutics | EFFECT：其他

SEC announcement ·  02/09 06:04
Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on February 8, 2024. The notice indicates that the company's Form S-3 filing, associated with File Number 333-276794, is now effective as of 4:00 P.M. on the stated date. This development is a significant step for Arcutis Biotherapeutics, as it pertains to the company's registration statement under the SEC regulations.
Arcutis Biotherapeutics, Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on February 8, 2024. The notice indicates that the company's Form S-3 filing, associated with File Number 333-276794, is now effective as of 4:00 P.M. on the stated date. This development is a significant step for Arcutis Biotherapeutics, as it pertains to the company's registration statement under the SEC regulations.
在美国上市的公司Arcutis Biotherapeutics, Inc. 已于2024年2月8日收到美国证券交易委员会（SEC）的生效通知。该通知指出，该公司提交的与文件编号333-276794相关的S-3表格现已于规定日期下午4点生效。这一发展是Arcutis Biotherapeutics迈出的重要一步，因为它与该公司根据美国证券交易委员会法规发布的注册声明有关。
在美国上市的公司Arcutis Biotherapeutics, Inc. 已于2024年2月8日收到美国证券交易委员会（SEC）的生效通知。该通知指出，该公司提交的与文件编号333-276794相关的S-3表格现已于规定日期下午4点生效。这一发展是Arcutis Biotherapeutics迈出的重要一步，因为它与该公司根据美国证券交易委员会法规发布的注册声明有关。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息